A Novel Strategy for Physiologically Based Predictions of Human Pharmacokinetics
Top Cited Papers
- 1 January 2006
- journal article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 45 (5) , 511-542
- https://doi.org/10.2165/00003088-200645050-00006
Abstract
The major aim of this study was to develop a strategy for predicting human pharmacokinetics using physiologically based pharmacokinetic (PBPK) modelling. This was compared with allometry (of plasma concentration-time profiles using the Dedrick approach), in order to determine the best approaches and strategies for the prediction of human pharmacokinetics. PBPK and Dedrick predictions were made for 19 F. Hoffmann-La Roche compounds. A strategy for the prediction of human pharmacokinetics using PBPK modelling was proposed in this study. Predicted values (pharmacokinetic parameters, plasma concentrations) were compared with observed values obtained after intravenous and oral administration in order to assess the accuracy of the prediction methods. By following the proposed strategy for PBPK, a prediction would have been made prospectively for approximately 70% of the compounds. The prediction accuracy for these compounds in terms of the percentage of compounds with an average-fold error of z/F), terminal elimination half-life (t½), peak plasma concentration (Cmax), area under the plasma concentration-time curve (AUC) and time to reach Cmax (tmax), respectively. For the other 30% compounds, unacceptable prediction accuracy was obtained in animals; therefore, a prospective prediction of human pharmacokinetics would not have been made using PBPK. For these compounds, prediction accuracy was also poor using the Dedrick approach. In the majority of cases, PBPK gave more accurate predictions of pharmacokinetic parameters and plasma concentration-time profiles than the Dedrick approach. Based on the dataset evaluated in this study, PBPK gave reasonable predictions of human pharmacokinetics using preclinical data and is the recommended approach in the majority of cases. In addition, PBPK modelling is a useful tool to gain insights into the properties of a compound. Thus, PBPK can guide experimental efforts to obtain the relevant information necessary to understand the compound’s properties before entry into human, ultimately resulting in a higher level of prediction accuracy.Keywords
This publication has 67 references indexed in Scilit:
- Prediction of Hepatic Metabolic ClearanceClinical Pharmacokinetics, 2001
- Critique of Prospective Allometric Scaling: Does the Emperor Have Clothes?The Journal of Clinical Pharmacology, 2000
- Prediction of Hepatic Metabolic Clearance Based on Interspecies Allometric Scaling Techniques and In Vitro-In Vivo CorrelationsClinical Pharmacokinetics, 1999
- Physiological Parameter Values for Physiologically Based Pharmacokinetic ModelsToxicology and Industrial Health, 1997
- Use of a Biophysical-Kinetic Model to Understand the Roles of Protein Binding and Membrane Partitioning on Passive Diffusion of Highly Lipophilic Molecules Across Cellular BarriersJournal of Drug Targeting, 1993
- Physiologic modeling of cyclosporin kinetics in rat and manJournal of Pharmacokinetics and Biopharmaceutics, 1991
- Prediction of the volumes of distribution of basic drugs in humans based on data from animalsJournal of Pharmacokinetics and Biopharmaceutics, 1984
- Physiological pharmacokinetics of ethoxybenzamide based on biochemical data obtainedin vitro as well as on physiological dataJournal of Pharmacokinetics and Biopharmaceutics, 1982
- Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokineticsJournal of Pharmacokinetics and Biopharmaceutics, 1982
- Animal scale-upJournal of Pharmacokinetics and Biopharmaceutics, 1973